边缘区淋巴瘤的治疗方式与总生存、血液学缓解及潜在干燥病活动性的关系:一项多中心回顾性观察研究
该多中心回顾性观察研究纳入106例符合2016年ACR-EULAR标准的干燥病合并淋巴瘤患者,其中82例边缘区淋巴瘤患者接受观察等待、局部治疗或全身治疗。逆概率加权后,淋巴瘤诊断时接受全身治疗者新发干燥病系统活动风险降低(HR 0.43,95%CI 0.21-0.90),化疗联合抗CD20治疗较单药治疗改善淋巴瘤无进展生存(HR 0.36,95%CI 0.14-0.94)。
要点
- 干燥病相关淋巴瘤以黏膜相关淋巴组织淋巴瘤最常见(68/106,64%)。
- 边缘区淋巴瘤患者中,肺部定位与死亡相关(HR 7.92,95%CI 1.70-37.0)。
- 全身治疗较局部治疗或观察等待降低新发干燥病系统活动风险(HR 0.43)。
核心结论
- 对干燥病相关淋巴瘤采用全身治疗策略而非局部治疗或观察等待,可降低新发干燥病系统活动风险;联合治疗与淋巴瘤复发风险降低相关。
研究设计与样本
- 多中心、回顾性、观察性研究,纳入2016年ACR-EULAR标准干燥病且未满足其他结缔组织病诊断标准、2020年1月1日前诊断淋巴瘤的患者106例,来自巴黎两个专家中心、法国多中心前瞻性ASSESS队列及Club Rhumatismes et Inflammation注册医师。
- 采用逆概率治疗加权比较淋巴瘤治疗对淋巴瘤无进展生存、新发干燥病系统活动和总生存三个终点的影响,并进行探索性分析。
主要发现
- 106例干燥病合并淋巴瘤患者中,黏膜相关淋巴组织淋巴瘤68例(64%),其他边缘区亚型14例(13%),弥漫大B细胞淋巴瘤14例(13%)。
- 82例边缘区淋巴瘤患者中女性72例(88%)、男性10例(12%),淋巴瘤诊断时平均年龄57.5岁(SD 14.8);多变量分析显示肺部定位与死亡相关(HR 7.92,95%CI 1.70-37.0)。
- 82例边缘区淋巴瘤患者中,19例(23%)接受观察等待,13例(16%)接受一线局部治疗(手术或放疗),50例(61%)接受一线全身治疗;中位随访7年后,26例(32%)淋巴瘤复发,9例(11%)死亡,27例(33%)出现新发干燥病系统活动。
- 逆概率治疗加权后,淋巴瘤诊断时接受全身治疗的患者新发干燥病活动风险降低(HR 0.43,95%CI 0.21-0.90)。
- 一线化疗联合抗CD20治疗(n=32)较单药治疗(n=18)改善淋巴瘤无进展生存(HR 0.36,95%CI 0.14-0.94);联合治疗与单药治疗在新发干燥病系统活动或总生存方面无差异。
关键数值与推荐
- 干燥病诊断依据2016年美国风湿病学会-欧洲抗风湿病联盟标准,且不满足其他结缔组织病诊断标准。
- 淋巴瘤诊断时间在2020年1月1日之前。
- 边缘区淋巴瘤肺部定位与死亡的HR为7.92(95%CI 1.70-37.0)。
- 全身治疗与新发干燥病系统活动的HR为0.43(95%CI 0.21-0.90)。
- 化疗联合抗CD20治疗与淋巴瘤无进展生存的HR为0.36(95%CI 0.14-0.94)。
临床怎么用
- 原文结论认为,对干燥病相关淋巴瘤采用全身治疗策略而非局部治疗或观察等待可降低新发干燥病系统活动风险,联合治疗与淋巴瘤复发风险降低相关。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Sjögren's disease is the autoimmune disease with the highest risk of lymphoma development. There is no consensus on the optimal way to manage Sjögren's disease complicated by lymphoma. We aimed to describe characteristics, therapeutic strategies, and outcomes of non-Hodgkin lymphoma associated with Sjögren's disease, and their effect on lymphoma and Sjögren's disease prognoses. METHODS: We did a multicentre, retrospective, observational study including patients with Sjögren's disease according to the 2016 American College of Rheumatology-European League Against Rheumatism criteria who did not fulfil diagnostic criteria for other connective tissue diseases. We included patients with a lymphoma diagnosis made before Jan 1, 2020, from two expert centres in Paris (France); from the French, multicentre, prospective Assessment of Systemic Signs and Evolution of Sjögren's Syndrome cohort; and via practitioners registered with the Club Rhumatismes et Inflammation. Using inverse probability of treatment weighting, the effect of lymphoma treatment was compared in relation to three endpoints: lymphoma progression-free survival, new Sjögren's disease systemic activity, and overall survival. Exploratory analyses also aimed to identify factors associated with lymphoma relapse, new Sjögren's disease systemic activity, and overall survival. People with lived experience were not involved in this research. FINDINGS: 106 patients with Sjögren's disease who developed lymphoma were included in the study. The most frequent histological subtype was mucosa-associated lymphoid tissue lymphoma (68 [64%] of 106 patients), followed by other marginal zone subtypes (14 [13%] of 106 patients) and diffuse large B-cell lymphoma (14 [13%] of 106 patients). Among the 82 patients with marginal zone lymphoma (72 [88%] women and ten (12%) men; mean age at lymphoma diagnosis 57·5 years [SD 14·8]), multivariable analysis showed that pulmonary localisation was associated with mortality (hazard ratio [HR] 7·92 [95% CI 1·70-37·0]). A watch and wait approach was proposed in 19 (23%) of 82 patients with marginal zone lymphoma, 13 (16%) had first-line localised treatment (surgery or radiotherapy), and 50 (61%) had first-line systemic treatment. After a median follow-up of 7 years, 26 patients (32%) had lymphoma relapse, nine (11%) died, and 27 (33%) had new Sjögren's disease systemic activity. After inverse probability of treatment weighting, patients with systemic treatment at lymphoma diagnosis had a reduced risk of new Sjögren's disease activity (HR 0·43 [95% CI 0·21-0·90]). When comparing patients treated with a combination of chemotherapy and anti-CD20 therapy (n=32) with patients treated with monotherapy (n=18) as a first-line therapy for lymphoma, lymphoma-progression-free survival was improved in patients treated with combination therapy (HR 0·36 [95% CI 0·14-0·94]). The were no differences in new Sjögren's disease systemic activity or overall survival according to combination therapy or monotherapy. INTERPRETATION: A systemic treatment strategy for Sjögren's disease-associated lymphoma, rather than localised treatment or a watch and wait strategy, reduces the risk of new Sjögren's disease systemic activity and combination therapy is associated with decreased risk of lymphoma relapse. FUNDING: None.
引用
- Rocca J, Beydon M, Le Guern V, et al. Treatment modalities of marginal zone lymphoma and overall survival, haematological response, and underlying Sjögren's disease activity: a multicentre, retrospective, observational study. Lancet Rheumatol. 2024. PMID: 39182508. doi:10.1016/S2665-9913(24)00198-X
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。